Novo Nordisk
ACTIVENovo Nordisk A/S
Industrial manufacturer
Danish pharmaceutical company specializing in diabetes and obesity medications (e.g. Ozempic, Wegovy); publicly listed.
Founded1923
HQBagsvaerd
Novo Nordisk
Founded 1923 · Bagsvaerd, DenmarkNovo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsvaerd, with origins dating back to 1923 (its current form was created in 1989 through the merger of Novo Industri and Nordisk Gentofte). The company manufactures and markets pharmaceutical products, primarily diabetes and obesity medications and devices, including the semaglutide-based Ozempic and Wegovy. Novo Nordisk is listed on Nasdaq Copenhagen (NOVO-B) and as an ADR on the NYSE (NVO). In 2025 it employed 68,794 people with revenue of DKK 309.1 billion. Its CEO is Maziar Mike Doustdar (since August 2025).
Founders
Domain of activity
1 areas · 2 technologies · 2 industriesWhat they do1Areas
- Biotech / Drug Discovery
How they do it2Technologies
- Generative AI
- Foundation Models
Who for2Industries
- Pharma & biotech
- Healthcare
Global presence
HQ Bagsvaerd · 1 regionsGlobal
Scale & funding
founded 19231923founded
68,794 (2025)employees
maturedevelopment stage
Publiclisted
activestatus
Profile & metadata
4 classification · 2 external linksClassification
- Statusactive
- Development stagemature
- Listed onYes
- Organization typeIndustrial manufacturer
External links
